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Abstract: There is increasing interest to use oral cholera
vaccination as an additional strategy to water and
sanitation interventions against endemic and epidemic
cholera. There are two internationally-available and WHO-
prequalified oral cholera vaccines: an inactivated vaccine
containing killed whole-cells of V. cholerae O1 with
recombinant cholera toxin B-subunit (WC/rBS) and a
bivalent inactivated vaccine containing killed whole cells
of V. cholerae O1 and V. cholerae O139 (BivWC). The
efficacy, effectiveness, direct and indirect (herd) protec-
tion conferred by WC/rBS and BivWC are well established.
Yet governments may need local evidence of vaccine
impact to justify and scale-up mass oral cholera vaccina-
tion campaigns. We discuss various approaches to assess
oral cholera vaccine protection, which may be useful to
policymakers and public health workers considering
deployment and evaluation of the vaccine.
Introduction
Cholera continues to be a public health threat in many
developing countries as highlighted by recent outbreaks in Angola,
Zimbabwe, Haiti, the Democratic Republic of the Congo and
other regions of Africa. Ensuring clean water, sanitation and
hygiene constitute the main strategies for the prevention of the
disease. But in endemic areas with seasonal cholera outbreaks,
these basic needs are often not met and cholera outbreaks during
natural or man-made disasters are usually associated with
infrastructure breakdown. In October 2009, the World Health
Organization’s Strategic Advisory Group of Experts on Immuni-
zation recommended that oral cholera vaccination should be
considered as a reactive strategy during outbreaks, in addition to
the already recommended preventive use of oral cholera
vaccination in endemic areas [1]. The WHO has initiated the
development of an oral cholera vaccine (OCV) stockpile, which
will supply the vaccine in areas of emergency need [2].
Sinclair and co-workers have previously reviewed the safety,
relative effectiveness and duration of protection of the different
types of OCV [3]. Currently, there are two internationally-
available and WHO-prequalified OCVs: an inactivated vaccine
containing killed whole-cells of V. cholerae O1 with recombinant B-
subunit of cholera toxin (WC/rBS) marketed as DukoralTM and a
bivalent inactivated vaccine containing killed whole cells of
V. cholerae O1 and V. cholerae O139 (BivWC) marketed as
ShancholTM. Both WC/rBS and BivWC are given in 2 doses.
WC/rBS is taken with a bicarbonate buffer, which protects the B-
subunit component from degradation by gastric acid but BivWC
does not require a buffer.
Large-scale efficacy trials of earlier versions of WC vaccine with
and without the B subunit in Matlab, Bangladesh showed that the
vaccine is safe and provides 85% protection for 4–6 months after
vaccination, 62% protection at 1 year, and 58% protection at 2
years [4]. Protection in children 6 years of age was 100% for the
first 4–6 months but decreased rapidly thereafter. A clinical trial of
the WC/rBS among military volunteers in Peru confirmed
significant protective efficacy against cholera (86%) in the short
term [5]. Post-licensure, observational studies of WC/rBS using a
case-control approach in Mozambique [6] and a cohort design in
Zanzibar [7] showed vaccine effectiveness of 78% and 79%,
respectively, during the year after vaccination. In addition to
providing direct protection to vaccine recipients, WC/rBS confers
significant herd protection to neighboring non-vaccinated indi-
viduals [7,8]. It has been deployed in various mass campaigns
vaccinating those who are healthy, two years of age and older or
not pregnant [9], but is expensive and used mainly by Western
travellers. Aside from protection against cholera, WC/rBS (unlike
BivWC) contains the B-subunit of cholera toxin, which cross-
protects against heat-labile toxin producing Escherichia coli diarrhea
for 3 to 5 months following vaccination [10,11].
A large-scale efficacy trial of BivWC in India showed that the
vaccine is safe and confers 67% protection against cholera within
two years of vaccination [12], 66% at three years [13] and 65% at
five-years [14] of follow-up. BivWC has also been shown to confer
herd protection [15]. The vaccine has been used in various mass
campaigns vaccinating those who are healthy, one year of age or
older and not pregnant [9] but there are, as yet, no published
studies of assessments of Shanchol effectiveness under real field
conditions.
Despite available data on the protection conferred by OCVs,
governments may require local evidence of impact to justify an
initial vaccination campaign, for advocacy, to maintain public
confidence in the vaccine or to guide future decisions regarding
scaling-up of vaccination or inclusion of the vaccine in their public
health program. This is an overview of epidemiologic methods
that may be employed to assess the protection conferred by mass
oral cholera vaccination campaigns and the requirements to
carryout such assessments. To our knowledge, there have been
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only two published post-licensure observational studies that
measured direct and indirect effectiveness of currently available
OCVs [6,7]. We drew on insights from these studies, along with
general epidemiologic guidelines, experience with other vaccines
and mathematical models, to provide a general overview of
assessing the impact of OCVs. This paper is divided into two
general sections: field studies to estimate OCV effectiveness and
mathematical modeling to assess the potential impact of OCV.
These approaches are summarized in Table 1.
Analysis
1. Field studies to estimate OCV effectiveness
When estimating the protection conferred by mass oral cholera
vaccination in a developing country setting, the distinction must be
made between efficacy and effectiveness [16]. Vaccine efficacy is
generally measured pre-licensure using a double-blind randomized
controlled trial (RCT) study design under ideal research condi-
tions. Vaccine effectiveness is the protection conferred when the
vaccine is used under routine conditions in the community.
Vaccine impact may have a broader connotation than vaccine
effectiveness, including protection from cholera as well as
reductions in cases and deaths. This section will focus on methods
to assess the effectiveness of mass oral cholera vaccination
campaigns in a developing country setting.
The effectiveness of OCV, measured at the population level,
rests on vaccine efficacy and several factors. Decreased immuno-
genicity of the vaccine caused by, for example, the improper
storage and transport of the vaccine or the inappropriate
administration and timing of doses may lower effectiveness.
Effectiveness may also be affected by immune response and other
host factors of the population, location (e.g. endemic area with
seasonal outbreaks versus natural disaster site with no previous
cholera), cholera transmission intensity, as well as the timing and
conditions under which the OCV mass vaccination is conducted
(e.g. pre-emptive versus reactive campaign).
Mass OCV campaigns protect those who are vaccinated from
cholera and result in a decrease in the number of individuals
shedding V. cholerae in the community. This reduces the V. cholerae
biomass in the immediate environment, lessening the likelihood
of residents (vaccinated and unvaccinated) becoming infected.
The protection conferred to the vaccinated individuals due to
vaccine-induced immune response is direct protection, whereas
that conferred to the non-vaccinated is indirect (herd) protection.
Considering the large indirect effect of OCV [7,8,15] and given
the importance that this herd effect can have on assessing
outcome, anyone interested in an OCV campaign should ideally
plan their intervention and assessment of protection in a manner
that takes herd immunity into account. Furthermore, the use of
OCV in programs to control endemic cholera has been found to
be cost-effective when herd effect is included in the calculations
[17].
Several studies have demonstrated the direct and indirect
protection conferred by BivWC and WC/rBS [3–9,12–15] in
various settings. Conducting further RCTs would be expensive
and require ethical justification for withholding the vaccine from a
control group. When such study designs cannot be used to obtain
local data, observational study designs have to be employed but
careful attention has to be paid to reliability issues, including bias,
misclassification and confounding. The absence of randomly
selected control groups in these observational studies render such
designs vulnerable to bias. Individuals included in these observa-
tional studies decide whether or not to take the vaccine and also
decide whether or not to seek treatment from a health care
provider if he or she develops acute watery diarrhea. (The
individual ‘‘decisions’’ may relate to access to the vaccine program
as well as access to the treatment options). These inherent
differences in characteristics and health-seeking behavior between
the vaccinated and unvaccinated groups can bias measurements of
OCV effectiveness and are the main limitation of measuring
vaccine effectiveness using a non-randomized design. For example,
those who choose not to participate in an OCV campaign may
also not seek treatment for acute, watery diarrhea, resulting in a
lower detection of cholera cases among the non-vaccinated and
thereby falsely reducing the effectiveness estimate. Any factor that
differentially raises or lowers the detection of cholera cases in
either the vaccinated or unvaccinated group will bias the OCV
effectiveness estimate. Since patients with diarrhoea are usually
unaware of whether they have cholera or not, any factor that
differentially raises or lowers the detection of cholera cases will
likely do the same to non-cholera cases. Recent observational
studies assessing OCV effectiveness [6,7] have incorporated
concurrently conducted ‘‘bias-indicator’’ studies of non-cholera
diarrhoea (discussed below). Such parallel studies can detect but
Table 1. Methods to assess the impact of mass oral cholera vaccination campaigns.
Comparison between Outcome
1. Field studies of effectiveness
a. Main observational designs:
Case-control design Proportion vaccinated among the cholera cases and proportion
vaccinated among the healthy controls
Odds ratio of having received oral
cholera vaccine among the cholera
cases relative to healthy controls
Cohort design Cholera incidence in the vaccinated and cholera
incidence in the unvaccinated
Relative risk of cholera among the
vaccinated relative to the
unvaccinated cohorts
b. Geographic Information System approach Cholera incidence in the non-vaccinated residents of neighborhoods
with high vaccine coverage and cholera incidence in the non-
vaccinated residents of neighborhoods with low vaccine coverage
Test for trend
c. Before-and-after comparison Cholera incidence in the population before vaccination and
cholera incidence in the same population after deployment of OCV
Percentage decline of cholera
incidence or elimination
2. Mathematical modeling Various vaccination strategies in the defined population and no
vaccination in the defined population
Estimated reduction in cholera cases
doi:10.1371/journal.pone.0088139.t001
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not remedy bias due to differential diarrhoea care-seeking
behaviour. The aim of the parallel study is to evaluate whether
there is unexpected protection from OCV against non-cholera
diarrhoea, resulting from differential seeking of medical care for
diarrhoea among those who chose to receive the vaccine and those
who did not. Using non-cholera diarrhoea as a bias-indicator
should only be done if the stool culture methods to confirm cholera
are rigorously checked (for example, by quality assurance testing
and cross checking of samples in a reference laboratory) as poor
stool culture techniques resulting in low sensitivity may result in
misclassification of cholera as non-cholera cases.
There is also the problem of potential confounding in
observational studies. Potential confounders in OCV effectiveness
assessments include age, sex, socio-economic status, educational
level, sanitation, water supply and distance to a vaccination center
and treatment facility. These factors may be associated with both
participation in the vaccination campaign and with the risk for or
the detection of cholera. In RCT studies, confounding is avoided
by random distribution of individuals between the vaccinated and
unvaccinated groups. In observational studies, potential confound-
ers have to be considered and controlled for by other means.
Confounding can be adjusted for in the design (through matching)
or during the analysis (through stratification or multi-variable
analysis). For example, in case-control studies, matching for age,
sex and neighborhood may help ensure comparability between
cases and controls. During the analysis, a comparison of
characteristics between cases and controls (in case-control studies)
and between the vaccinated and unvaccinated individuals in the
population (in cohort studies) may provide an indication of
comparability; statistical methods may be used to adjust for these
confounders. Methods to control confounding in the analysis can
range from simple stratification to multivariate regression to
produce adjusted effectiveness results.
There are several basic components that are essential for the
assessment of both direct and indirect OCV effectiveness following
a mass vaccination campaign, which are shown as a checklist in
Figure S1. The first essential step is the development of standard
operating procedures for the OCV campaign. A detailed
discussion of the planning and logistics of mass OCV campaigns
are available from WHO [18]. The validity of the OCV protection
estimates will depend on how well the components are
implemented including the completeness of case capture from
the target population, the uniform application of the case
definition and the ascertainment of vaccination status. Important-
ly, field studies to assess OCV protection can only be carried out if
there are a sufficient number of cases following the vaccination
campaign. OCV campaigns with very high coverage may
interrupt cholera transmission resulting in the absence of cases.
The timing of the vaccination campaign is also crucial in the
assessment of effectiveness. The outbreak curve of cholera cases
may already be on the downward slope or the outbreak may be
ending when the vaccination campaign is carried out.
a. Observational study designs to estimate OCV direct
protection. There are different study designs [19–21] that may
be used to assess OCV direct protection following a mass
vaccination campaign. Case-control and cohort designs were
selected as the main approaches based on their applicability in
assessing OCV effectiveness, as well as previous experience with
their use.
In a case-control design, cholera cases are compared with
controls who are purposefully selected and comparable to the cases
except for not having diarrhea during the focal time. The focal
time is the period from the mass vaccination until the case
develops cholera. Cases and controls should be from the defined
population (also known as source population). Controls may be
matched to each case for variables known to be associated with the
exposure and outcome (e.g. age, sex and neighborhood) or
unmatched and confounders adjusted for during the analysis.
Matching of cases and controls may increase the likelihood that
the detected outcome (cholera or no cholera) is due to differences
in the exposure (vaccination or no vaccination) rather than due to
confounders such as age, sex and neighborhood. But matching
complicates the analysis and makes it impossible to evaluate the
impact of the factor on which matching is done.
In a previous study [6], aside from matching for the above
characteristics and to further ensure similar risk for cholera,
controls were selected from the neighborhood of the case using a
standard procedure (i.e. controls were chosen through a walk
around procedure starting from every third house to the right of
the case’s house). Coming from the same neighborhood was
considered as a proxy for matching of socio-economic status,
sanitation and water supply. Generally, 2 to 4 controls per case are
included; there is no practical increase in study power when more
than 4 controls per case are included [22]. Instead of neighbor-
hood controls, using hospital controls (for example confirmed
shigella cases) would match cholera cases in terms of health care
utilization. However in developing country settings where cholera
occurs and where these studies are to take place, there is often
limited facility for diagnosing the cause or causes of a diarrheal
illness; laboratory confirmation of cholera will be difficult enough.
In a case-control design, OCV effectiveness is calculated by
comparing the odds ratio (OR) of vaccination between the cases
and controls [19]. The basic formula for calculating the OR and
vaccine effectiveness are shown in Table 2. In the study in Beira,
Mozambique, there were 43 cholera cases from the defined
population during one year following the mass vaccination [6].
172 matched healthy controls (4 per case) were included in the
study. 10/43 (23%) of the cholera cases and 94/172 (55%) of the
matched controls received at least one dose of OCV resulting in an
unadjusted OR of 0.19. The OR, adjusted for differing
characteristics between cases and controls, was 0.22 and the
calculated vaccine effectiveness within one year following vacci-
nation was 78% (i.e. [1–0.22] * 100%).
A cohort study to assess OCV effectiveness may be appropriate
when a defined population can be followed prospectively after a
mass vaccination campaign. This study design is considered as
quasi-experimental, that is, OCV is not randomly allocated but
nonetheless a study is conducted of the subjects grouped according
to whether they were or were not vaccinated. Vaccine effectiveness
is measured using the incidence of cholera among the vaccinated
and unvaccinated persons in the population. The basic formula is:
vaccine effectiveness (%) = (Incidence in unvaccinated–Incidence
in vaccinated/Incidence in unvaccinated or relative risk)6100
[19].
Table 2. Formula for calculating odds ratio (OR) and vaccine
effectiveness in studies using a case-control design.
Cases Controls
Vaccinated a B
Unvaccinated c D
OR= ad/bc
Vaccine effectiveness (%) = (1–OR)6100.
doi:10.1371/journal.pone.0088139.t002
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It is important to ensure that efforts to detect cases among
unvaccinated and vaccinated persons are equal. As discussed
above, presentation to health centers may be associated with
previous participation or non-participation in the mass vaccination
campaign. There may also be an unequal chance of exposure to
cholera between vaccine recipients and non-recipients; a compar-
ison of characteristics between vaccine recipients and non-
recipients may provide an indication of the comparability of both
groups and may be used to adjust the statistical calculations.
In the study in Zanzibar, 23,921 (50%), 3,757 (8%) and 20,500
(42%) of the target population of 48,178, received two, one and
zero OCV doses, respectively, during the mass vaccination [7].
Vaccine recipients differed in several aspects from those who did
not receive the vaccine. Vaccine recipients were more likely to be
female and younger that non-recipients. Vaccine recipients were
less likely to drink tap water, more likely to have had a recent
history of diarrhea, to live in less densely populated areas and to
live in areas with higher neighborhood-level vaccine coverage. 42
cholera cases were detected within 14 months after the mass
vaccination campaign. Six of 23,921 recipients of two vaccine
doses had cholera (incidence of 0.25 per 1000 persons) compared
with 33 of 20,500 unvaccinated people (incidence of 1.61 per 1000
persons). The RR, adjusted for significantly different variables
between the vaccinated and unvaccinated groups was 0.21.
Receipt of two complete doses of vaccine resulted in protective
effectiveness of 79% (i.e. [1–0.21] * 100%).
To check for possible bias resulting from the differential seeking
of medical care among those who received the vaccine and those
who did not, a bias-indicator study may be conducted in parallel
with the primary cholera study [6,7]. For a case-control design,
aside from the primary cholera assessment, a concomitant study
may be simultaneously done wherein non-cholera diarrhoea cases
are matched with healthy controls and vaccine effectiveness
against non-cholera diarrhoea calculated. For cohort studies, the
incidence of non-cholera diarrhoea among the vaccinated and
unvaccinated persons in the study population may be used to
calculate vaccine effectiveness against non-cholera diarrhoea. The
lack of OCV protection against non-cholera diarrhea would
suggest the absence of bias due to the differential seeking of
medical care among the vaccinated and unvaccinated. SInce WC/
rBS provides short-term protection against heat-labile toxin
producing E. coli diarrhea [10,11], bias-indicator studies incorpo-
rated into assessments of WC/rBS effectiveness should start 3 to 5
months after the mass vaccination to exclude patients who are
cross-protected against enterotoxigenic E. coli.
In the Beira study, a concurrently conducted bias-indicator
assessment comparing persons with noncholeraic diarrhea and
healthy controls in the same population found no protection
associated with receipt of the vaccine, which was interpreted as
the absence of bias in the primary study [6]. In the Zanzibar study,
the potential for bias was also investigated by assessing whether the
vaccine protects against non-cholera diarrhea [7]. Surprisingly,
not only did vaccination not protect against non-cholera diarrhea
as expected, but it was associated with a higher risk of non-cholera
diarrhea. This was interpreted as an absence of bias and that
people who were at high risk for diarrhea were more likely to
participate in the vaccination campaign than those who were not.
Other study designs may be considered. For example, a vaccine
probe approach may be used. Unlike studies of vaccine efficacy or
effectiveness that assess proportionate disease reduction between
the vaccinated and unvaccinated, vaccine probe studies measure
absolute disease reduction, known as the ‘‘vaccine preventable
disease incidence’’ [23]. The distinction is important as vaccines
may have an impact on disease severity but not on incidence.
Vaccine probe studies are particularly useful when laboratory
diagnosis is difficult (e.g. pneumococcal and Haemophilus influenzae
type b disease) or when the infection may lead to complications at
which time etiologic confirmation may not be possible (e.g.
influenza leading to secondary bacterial pneumonia) [23]. Ideally
vaccine probe studies should involve randomization and blinding,
which may be difficult to implement for licensed vaccines such as
OCV.
Alternative approaches such as case-cohort designs, interrupted
time series analysis or case-control studies using different control
groups may also be considered. There is as yet no experience with
the use of these designs in the evaluation of OCV effectiveness.
b. Geographic Information System (GIS) approach to
estimate OCV indirect protection. A straightforward
approach to measure herd immunity is to conduct cluster
randomization trials, in which groups of individuals serve as the
units randomised to the vaccine and control arms of the trial [24].
Indirect vaccine protection is measured by comparing the disease
incidence in the non-vaccinated members of clusters assigned to
receive the vaccine versus those in clusters receiving placebo.
However, during post-licensure use of OCV in mass vaccination
campaigns, the distribution of vaccine is not randomised;
innovative observational methods have to be utilized to assess
herd protection.
Geographic Information System (GIS) mapping may be utilized
to assess indirect protection conferred by OCV deployed during
mass vaccination campaigns. The GIS method takes advantage of
varying levels of vaccine uptake within neighbourhood contacts
of the individual that may occur due to chance or differing rates of
participation. To evaluate indirect protection, cholera incidence
among non-vaccinated residents of neighborhoods with high
vaccine coverage is compared with cholera incidence among non-
vaccinated residents of neighborhoods with low vaccine coverage
(Table 1).
Aside from the components of OCV effectiveness assessment
discussed above and in Figure S1, there are additional require-
ments to measure indirect protection using the GIS approach.
First, household mapping of the target population is required to
carryout this analysis. A census database of the target population is
essential and this will be correlated to a map of the area using GIS.
The correlation is generally done using a ground survey to link
each household with a geographic point on the map. The census
database is also correlated with the vaccination database such that
participants and non-participants of the mass vaccination cam-
paign can be linked to a household geographic location. Cholera
cases identified during surveillance will also be linked to a
household geographic location.
Next, it is important to define an appropriate (optimal) size of
neighborhood for computing neighborhood-level vaccine coverage
for each household in order to evaluate geographic variation of
vaccine coverage within the study area. The premise behind
computing neighbourhood-level vaccine coverage is that individ-
uals are more likely to interact with those who are close to them in
space than those located further away [25]. Thus, disease rates
within each neighbourhood represent exposure from an individ-
ual’s contact network that leads to the transmission of cholera [26–
28]. The probability of becoming infected within each neighbour-
hood depends on the number of infected and vaccinated
individuals within the contact network. Different neighborhood
sizes need to be investigated to find the optimal neighborhood size.
The underlying assumption for defining an optimal neighborhood
size is that it should not be too small as to yield an unstable result
and not too big such that local detail is obscured. Different
neighborhood sizes can be tested for suitability using Hartley’s
Assessment of Oral Cholera Vaccine Impact
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variance ratio test [29], as has been done elsewhere [7,8].
Computation of the neighborhood level vaccine coverage using
the GIS approach is shown in Figure 1 [30]. Contour mapping
techniques (ESRI, Redlands, CA, USA) may be used to show
spatial patterns of neighborhood-level vaccine coverage in the
study area, as has been previously done [7,8]. If multiple
neighbourhood sizes are used, there is a risk of false positives
and the p-value needs to be corrected for multiple comparisons
[31].
In mass vaccination campaigns, the neighborhood level vaccine
coverage is defined post hoc. Therefore, the approach can be
affected by many non-random factors affecting neighborhood level
vaccine coverage [7,8]. Care should be taken to adjust the analyses
for factors that might bias the association between levels of vaccine
coverage and the disease rates. And as with case-control and
cohort designs, a parallel bias-indicator GIS study may also be
incorporated in the assessment.
GIS methods employed in the Zanzibar study [7] showed that
cholera cases were mainly located outside the high-level vaccine
coverage areas. In contrast, non-cholera cases were randomly
distributed. There was a decrease in the incidence of cholera
among the non-vaccinated residents within a neighborhood as the
vaccine coverage in that neighborhood increased. Such an inverse
relation was not noted for non-cholera diarrhea (bias-indicator
study). A comparison of the risk for cholera in unvaccinated
residents between the highest and lowest neighborhood level
vaccine coverage showed a 75% indirect protection in the higher
coverage group compared with the lower coverage group.
c. Before-and-after comparison. When OCV is deployed
on a large-scale in an endemic area, particularly with the aim of
disease elimination, the annual incidence of cholera during the
period before and after deployment of the vaccine could be
compared to show vaccine impact, as has been done for other
vaccines [32,33]. If the annual number of cases is few, then a
cumulative incidence over a several year period may be utilized. A
before-and-after comparison would require continuing surveil-
lance for cholera prior to, during and following vaccination. An
observed reduction or elimination of cholera would suggest that
OCV reduced or interrupted V. cholerae transmission (likely
through the combination of direct and indirect protection).
However, a cause-and-effect relationship would be difficult to
establish since cholera outbreaks are unpredictable even over a
multi year time horizon and other factors such as improvements of
water supply and sanitation, changes in socio-economic status or
environmental factors affecting V. cholerae ecology [34] may
decrease disease transmission. Nevertheless, this method may be
useful to bolster confidence in OCV and as an indicator of when
and where repeat OCV campaigns may be necessary. Herd effects
Figure 1. Computation of neighborhood level vaccine coverage using a Geographic Information System approach.
doi:10.1371/journal.pone.0088139.g001
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may also be apparent in non-vaccinated age groups within the
same community and may be used assess indirect protection, as
has been done in other vaccination programs [35]. It would be
interesting to find out whether wide-scale mass OCV vaccination
in a relatively closed cholera-endemic environment (e.g. an island
community) without changes in water and sanitation infrastructure
could eliminate cholera.
2. Mathematical modeling to assess the potential impact
of OCV
Stochastic simulation models have been used to investigate the
potential control of endemic cholera using OCV. After the 1985
vaccine trial results from Matlab, Bangladesh [4] was reanalyzed
using the GIS approach to show herd protection from OCV [8],
Longini and co-workers used the same dataset to construct a
simulation model of varying vaccine coverage levels and cholera
illness [36]. They calculated that 50% OCV coverage in this
population would result in 89% reduction in cholera cases even
among the unvaccinated, and a 93% reduction overall in the
entire population. Their estimates would apply only where cholera
is endemic and population levels of immunity (from previous
exposure to the disease) are relatively high.
More recently, following the 2010–2011 cholera outbreak in
Haiti, various simulations were used to assess different vaccination
strategies [37]. The overall effectiveness of a vaccination strategy
was estimated as the percentage of cases averted with respect to
the baseline simulations in which vaccines were not used. The
most efficient reactive strategy found was to prioritize vaccination
of individuals living in cholera high-risk areas. In Haiti, the
population living along the lower Artibonite River was considered
as having a higher exposure to cholera and greater potential to
transmit the disease. The modeling showed that targeting one
million doses of vaccine to these areas, enough for two-dose
vaccination of 5% of the population, would decrease the number
of cases by 11%. The same strategy with enough vaccine for 30%
of the population with modest hygienic improvement could reduce
cases by 55% and save 3,320 lives.
Mathematical modeling is a valuable method to study cholera
outbreaks and to simulate the effect of different vaccination
strategies and other interventions. These calculations are useful to
determine the most optimal vaccination strategy (particularly
when there are an insufficient number of vaccine doses available)
and to guide local vaccination programmes and donor assistance.
But these estimates are only as good as the assumptions that are
used to calibrate the models [38]. There remains the need for field
studies to validate these approximations.
Discussion
In summary, we discussed various post-licensure approaches to
assess OCV protection. The study design chosen to measure OCV
effectiveness will depend on logistics and resources, e.g. whether it
is possible to recruit controls from the target population for a case-
control study or whether the target population can be followed
longitudinally for a cohort study. Because of the non-randomized
nature of these studies, there is a potential for bias and
confounding in these assessments and they should incorporate
procedures to assess and control for these. Evaluation of protection
may be done if there is incomplete OCV coverage of the target
population and if there are cholera cases following the mass
vaccination. It would not be possible to assess OCV protection
when there are few or no cholera cases detected after a campaign
except through before-and-after comparisons. The outcome from
these assessments should be interpreted with caution, keeping in
mind study limitations and should consider previous evidence.
Mathematical modelling may also be used to assess the impact of
various vaccination strategies tailored to different outbreak
scenarios.
This paper is limited because it does not provide detailed
information on methodology. On the other hand, the article brings
together information from various studies and provides a general
overview of the methods to assess the impact of OCVs. Donor and
implementing agencies, as well as in Ministries of Health staff in
many countries where cholera is endemic, may not be fully aware
of the methods that are available to assess the impact of OCVs.
Compared with other vaccines given in mass campaigns, OCVs
are underutilized and country-specific studies of protection may be
useful to inform policy decisions and provide additional support
for more widespread use of OCVs in areas affected by cholera.
There is a need for detailed guidelines on assessing the impact of
OCV that include protocol and case report form templates, such
as those available for other vaccines [39,40].
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